Table 2

Systemic outcomes of adalimumab therapy, expressed per-person ‘at risk’

Outcome6 weeks6 months12 months18 months24 months30 months
Per-personCharacteristic required to be ‘at risk’Events/at riskRate per 100 (95% CI)Events/at riskRate per 100 (95% CI)Events/at riskRate per 100 (95% CI)Events/at riskRate per 100 (95% CI)Events/at riskRate per 100 (95% CI)Events/at riskRate per 100 (95% CI)
Active patients
 Reduction of prednisolone to≤10 mg/day>10 mg/day at baseline5/862.5 (30.4 to 86.5)8/8100 (62.8 to 100*)6/785.7 (46.7 to 99.5)2/540.0 (11.6 to 77.1)4/4100 (45.4 to 100*)3/3100 (38.3 to 100*)
 Reduction in number of systemic steroid-sparing agents to ≤ 1>1 systemic steroid-sparing agent at baseline1/333.3 (5.6 to 79.8)2/366.7 (20.2 to 94.4)1/1100 (16.7 to 100*)0/0n/a0/0n/a0/0n/a
Inactive  patients
 Reduction of prednisolone to≤10 mg/day>10 mg/day at baseline4/4100 (45.4 to 100*)4/4100 (45.4 to 100*)3/3100 (38.3 to 100*)2/2100 (29.0 to 100*)2/2100 (29.0 to 100*)1/1100 (16.7 to 100*)
 Reduction in number of systemic steroid-sparing agents to ≤1>1 systemic steroid-sparing agent at baseline1/250.0 (9.5 to 90.5)1/250.0 (9.5 to 90.5)2/2100 (29.0 to 100*)1/1100 (16.7 to 100*)1/1100 (16.7 to 100*)1/1100 (16.7 to 100*)
  • *Indicates the Agresti-Coull CI was clipped at the upper endpoint.